miltefosine has been researched along with Hives in 1 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Excerpt | Relevance | Reference |
---|---|---|
"After 4 weeks of treatment, Urticaria Activity Score (UAS7) levels were substantially more reduced in miltefosine-treated patients (-6." | 9.17 | Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. ( Bieber, T; Biedermann, T; Brasch, J; Dominicus, R; Hunzelmann, N; Jakob, T; Magerl, M; Mahler, V; Maurer, M; Popp, G; Rother, M; Schäkel, K; Schlingensiepen, R; Schmitt, J; Siebenhaar, F; Simon, JC; Staubach, P; Wedi, B; Weidner, C, 2013) |
"After 4 weeks of treatment, Urticaria Activity Score (UAS7) levels were substantially more reduced in miltefosine-treated patients (-6." | 5.17 | Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. ( Bieber, T; Biedermann, T; Brasch, J; Dominicus, R; Hunzelmann, N; Jakob, T; Magerl, M; Mahler, V; Maurer, M; Popp, G; Rother, M; Schäkel, K; Schlingensiepen, R; Schmitt, J; Siebenhaar, F; Simon, JC; Staubach, P; Wedi, B; Weidner, C, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Magerl, M | 1 |
Rother, M | 1 |
Bieber, T | 1 |
Biedermann, T | 1 |
Brasch, J | 1 |
Dominicus, R | 1 |
Hunzelmann, N | 1 |
Jakob, T | 1 |
Mahler, V | 1 |
Popp, G | 1 |
Schäkel, K | 1 |
Schlingensiepen, R | 1 |
Schmitt, J | 1 |
Siebenhaar, F | 1 |
Simon, JC | 1 |
Staubach, P | 1 |
Wedi, B | 1 |
Weidner, C | 1 |
Maurer, M | 1 |
1 trial available for miltefosine and Hives
Article | Year |
---|---|
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria.
Topics: Chronic Disease; Double-Blind Method; Histamine Antagonists; Humans; Phosphorylcholine; Placebos; Ur | 2013 |